Systemic calciphylaxis

Manika Suryadevara; Scott J. Schurman; Steve K. Landas; Abraham Philip; Christopher B. Gerlach; Trisha Tavares; Abdul Kader Souid

doi:10.1002/pbc.21631

Systemic calciphylaxis

Manika Suryadevara, Scott J. Schurman, Steve K. Landas, Abraham Philip, Christopher B. Gerlach, Trisha Tavares, Abdul Kader Souid

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

An 11-year-old male developed systemic calciphylaxis during induction therapy for acute lymphoblastic leukemia. His predisposing conditions were hypercalcemia, supplements for pamidronate-induced hypocalcemia and hypophosphatemia and renal insufficiency. He died of cardiorespiratory arrest on the 20th day of induction treatment. Autopsy revealed extensive calcium deposits in the heart, lungs and kidneys. He had diffused alveolar damage, acute tubular necrosis, chronic pancreatitis and marked hepatic steatosis. Systemic calcium deposition may progress rapidly in children with hypercalcemia of malignancy. Since Pamidronate reduces mineral resorption from tissues, calcium and phosphate replacements increase systemic mineral deposits. Thus, mineral supplements should be considered only to combat symptoms.

Original language	English
Pages (from-to)	548-550
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	51
Issue number	4
DOIs	https://doi.org/10.1002/pbc.21631
Publication status	Published - Oct 2008
Externally published	Yes

Keywords

Calciphylaxis
Hypercalcemia
Leukemia
Pamidronate

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.21631

Cite this

@article{78eb0eedbc1a4f978178aebd56211c0c,

title = "Systemic calciphylaxis",

abstract = "An 11-year-old male developed systemic calciphylaxis during induction therapy for acute lymphoblastic leukemia. His predisposing conditions were hypercalcemia, supplements for pamidronate-induced hypocalcemia and hypophosphatemia and renal insufficiency. He died of cardiorespiratory arrest on the 20th day of induction treatment. Autopsy revealed extensive calcium deposits in the heart, lungs and kidneys. He had diffused alveolar damage, acute tubular necrosis, chronic pancreatitis and marked hepatic steatosis. Systemic calcium deposition may progress rapidly in children with hypercalcemia of malignancy. Since Pamidronate reduces mineral resorption from tissues, calcium and phosphate replacements increase systemic mineral deposits. Thus, mineral supplements should be considered only to combat symptoms.",

keywords = "Calciphylaxis, Hypercalcemia, Leukemia, Pamidronate",

author = "Manika Suryadevara and Schurman, {Scott J.} and Landas, {Steve K.} and Abraham Philip and Gerlach, {Christopher B.} and Trisha Tavares and Souid, {Abdul Kader}",

year = "2008",

month = oct,

doi = "10.1002/pbc.21631",

language = "English",

volume = "51",

pages = "548--550",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Systemic calciphylaxis

AU - Suryadevara, Manika

AU - Schurman, Scott J.

AU - Landas, Steve K.

AU - Philip, Abraham

AU - Gerlach, Christopher B.

AU - Tavares, Trisha

AU - Souid, Abdul Kader

PY - 2008/10

Y1 - 2008/10

N2 - An 11-year-old male developed systemic calciphylaxis during induction therapy for acute lymphoblastic leukemia. His predisposing conditions were hypercalcemia, supplements for pamidronate-induced hypocalcemia and hypophosphatemia and renal insufficiency. He died of cardiorespiratory arrest on the 20th day of induction treatment. Autopsy revealed extensive calcium deposits in the heart, lungs and kidneys. He had diffused alveolar damage, acute tubular necrosis, chronic pancreatitis and marked hepatic steatosis. Systemic calcium deposition may progress rapidly in children with hypercalcemia of malignancy. Since Pamidronate reduces mineral resorption from tissues, calcium and phosphate replacements increase systemic mineral deposits. Thus, mineral supplements should be considered only to combat symptoms.

AB - An 11-year-old male developed systemic calciphylaxis during induction therapy for acute lymphoblastic leukemia. His predisposing conditions were hypercalcemia, supplements for pamidronate-induced hypocalcemia and hypophosphatemia and renal insufficiency. He died of cardiorespiratory arrest on the 20th day of induction treatment. Autopsy revealed extensive calcium deposits in the heart, lungs and kidneys. He had diffused alveolar damage, acute tubular necrosis, chronic pancreatitis and marked hepatic steatosis. Systemic calcium deposition may progress rapidly in children with hypercalcemia of malignancy. Since Pamidronate reduces mineral resorption from tissues, calcium and phosphate replacements increase systemic mineral deposits. Thus, mineral supplements should be considered only to combat symptoms.

KW - Calciphylaxis

KW - Hypercalcemia

KW - Leukemia

KW - Pamidronate

UR - http://www.scopus.com/inward/record.url?scp=50249109389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249109389&partnerID=8YFLogxK

U2 - 10.1002/pbc.21631

DO - 10.1002/pbc.21631

M3 - Article

C2 - 18491373

AN - SCOPUS:50249109389

SN - 1545-5009

VL - 51

SP - 548

EP - 550

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

ER -

Systemic calciphylaxis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this